- Home
- CON vs APLS Comparison
CON vs APLS Comparison
Compare CON & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CON
- APLS
- Stock Information
- Founded
- CON 1979
- APLS 2009
- Country
- CON United States
- APLS United States
- Employees
- CON N/A
- APLS N/A
- Industry
- CON
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- CON
- APLS Health Care
- Exchange
- CON NYSE
- APLS Nasdaq
- Market Cap
- CON 2.7B
- APLS 2.2B
- IPO Year
- CON 2024
- APLS 2017
- Fundamental
- Price
- CON $20.76
- APLS $17.35
- Analyst Decision
- CON Strong Buy
- APLS Buy
- Analyst Count
- CON 7
- APLS 19
- Target Price
- CON $29.00
- APLS $37.67
- AVG Volume (30 Days)
- CON 787.2K
- APLS 2.0M
- Earning Date
- CON 07-31-2025
- APLS 07-31-2025
- Dividend Yield
- CON 1.21%
- APLS N/A
- EPS Growth
- CON N/A
- APLS N/A
- EPS
- CON 1.30
- APLS N/A
- Revenue
- CON $1,933,346,000.00
- APLS $775,839,000.00
- Revenue This Year
- CON $13.09
- APLS $1.01
- Revenue Next Year
- CON $7.35
- APLS $22.14
- P/E Ratio
- CON $15.91
- APLS N/A
- Revenue Growth
- CON 4.54
- APLS 48.04
- 52 Week Low
- CON $18.89
- APLS $16.10
- 52 Week High
- CON $24.81
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- CON N/A
- APLS 42.33
- Support Level
- CON N/A
- APLS $17.16
- Resistance Level
- CON N/A
- APLS $18.74
- Average True Range (ATR)
- CON 0.00
- APLS 0.65
- MACD
- CON 0.00
- APLS -0.09
- Stochastic Oscillator
- CON 0.00
- APLS 11.07
About CON CONCENTRA GROUP HOLDINGS PARENT INC
Concentra Group Holdings Parent Inc is a provider of occupational health services in the United States. The business is organized into three operating segments: occupational health centers, onsite health clinics, and other businesses.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.